Isocitrate dehydrogenase 1 Gene mutation is associated with prognosis in clinical low-grade gliomas

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Li, Ming Yang ^a,b   Wang, Yin Yan ^a,b   Cai, Jin Quan ^c   Zhang, Chuan Bao ^b   Wang, Kuan Yu ^d   Cheng, Wen ^e   Liu, Yan Wei ^b   Zhang, Wei ^a   Jiang, Tao ^a,b,f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; CANCER LOCALIZATION; CANCER PROGNOSIS; CHINESE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; COHORT ANALYSIS; DNA METHYLATION; FEMALE; FRONTAL LOBE; GENE MUTATION; GENETIC ASSOCIATION; GLIOMA; HEREDITY; HUMAN; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TP53 GENE; TREATMENT RESPONSE; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; PATHOLOGY; PROMOTER REGION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84938323123     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130872     Document Type: Article

References (24)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109. PMID: 17618441
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116: 597-602. doi: 10.1007/s00401-008-0455-2 PMID: 18985363
3. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-73. doi: 10.1056/NEJMoa0808710 PMID: 19228619
4. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009; 11: 341-7. doi: 10.1215/15228517-2009-025 PMID: 19435942
5. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174: 1149-53. doi: 10.2353/ajpath.2009.080958 PMID: 19246647
6. Gupta R, Webb-Myers R, Flanagan S, Buckland ME. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol. 2011; 64: 835-44. doi: 10.1136/jclinpath-2011-200227 PMID: 21752797
7. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103: 269-73. doi: 10.1111/j.1349-7006.2011.02134.x PMID: 22034964
8. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010; 75: 1560-6. doi: 10.1212/WNL.0b013e3181f96282 PMID: 20975057
9. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010; 16: 1597-604. doi: 10.1158/1078-0432.CCR-09-2902 PMID: 20160062
10. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997; 56: 1098-104. PMID: 9329453
11. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008; 9: 29-38. PMID: 18082451
12. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012; 7: e30339. doi: 10.1371/journal.pone.0030339 PMID: 22291938
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-12. doi: 10.1126/science.1164382 PMID: 18772396
14. Zhang CB, Bao ZS, Wang HJ, Yan W, Liu YW, Li MY, et al. Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol. 2014; 140: 45-51. doi: 10.1007/s00432-013-1519-9 PMID: 24149775
15. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150-4. doi: 10.1200/JCO.2009.21.9832 PMID: 19636000
16. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011; 17: 4588-99. doi: 10.1158/1078-0432.CCR-10-3194 PMID: 21558404
17. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010; 177: 2708-14. doi: 10.2353/ajpath.2010.100680 PMID: 21075857
18. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18: 636-45. PMID: 10653879
19. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. 2002; 8: 1117-24. PMID: 12006527
20. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004; 108: 49-56. PMID: 15118874
21. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol. 2013; 26: 922-9. doi: 10.1038/modpathol.2012.166 PMID: 23429602
22. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012; 18: 2490-501. doi: 10.1158/1078-0432.CCR-11-2977 PMID: 22415316
23. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-15. doi: 10.1016/S1470-2045(12)70164-X PMID: 22578793
24. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 2009; 73: 1792-5. doi: 10.1212/WNL.0b013e3181c34ace PMID: 19933982